Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar

期刊论文
出版模式：

开放获取
发表日期：

2024年5月8日

查看全文

Aung Myint Thu,
Aung Pyae Phyo,
Chanapat Pateekhum,
Jade D. Rae,
Jordi Landier,
Daniel M. Parker,
Gilles Delmas,
Wanitda Watthanaworawit,
Alistair R. D. McLean,
Ann Arya,
Ann Reyes,
Xue Li,
Olivo Miotto,
Kyaw Soe,
Elizabeth A. Ashley,
Arjen Dondorp,
Nicholas J. White,
Nicholas P. Day,
Tim J. C. Anderson,
Mallika Imwong,
Francois Nosten,
Frank Smithuis

摘要

Background

Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaquine (three rounds at monthly intervals) was conducted. The prevalence of artemisinin resistance during the elimination campaign (2013–2019) was characterized.

Methods

Throughout the six-year campaign Plasmodium falciparum positive blood samples from symptomatic patients and from cross-sectional surveys were genotyped for mutations in kelch-13—a molecular marker of artemisinin resistance.

Result

The program resulted in near elimination of falciparum malaria. Of 5162 P. falciparum positive blood samples genotyped, 3281 (63.6%) had K13 mutations. The prevalence of K13 mutations was 73.9% in 2013 and 64.4% in 2019. Overall, there was a small but significant decline in the proportion of K13 mutants (p < 0.001). In the MDA villages there was no significant change in the K13 proportions before and after MDA. The distribution of different K13 mutations changed substantially; F446I and P441L mutations increased in both MDA and non-MDA villages, while most other K13 mutations decreased. The proportion of C580Y mutations fell from 9.2% (43/467) before MDA to 2.3% (19/813) after MDA (p < 0.001). Similar changes occurred in the 487 villages where MDA was not conducted.

Conclusion

The malaria elimination program in Kayin state, eastern Myanmar, led to a substantial reduction in falciparum malaria. Despite the intense use of artemisinin-based combination therapies, both in treatment and MDA, this did not select for artemisinin resistance.